{
    "clinical_study": {
        "@rank": "56961", 
        "acronym": "CAREFOR", 
        "arm_group": {
            "arm_group_label": "Behavioral dietary intervention", 
            "arm_group_type": "Experimental", 
            "description": "Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies caloric restriction in patients with stage 0-I breast\n      cancer during surgery and radiation therapy. Reducing caloric intake may prevent disease\n      progression in patients with breast cancer. Radiation therapy uses high energy x rays to\n      kill tumor cells. Giving dietary intervention and radiation therapy together may kill more\n      tumor cells."
        }, 
        "brief_title": "Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy", 
        "condition": [
            "Ductal Breast Carcinoma in Situ", 
            "Invasive Ductal Breast Carcinoma", 
            "Invasive Lobular Breast Carcinoma", 
            "Lobular Breast Carcinoma in Situ", 
            "Recurrent Breast Cancer", 
            "Stage IA Breast Cancer", 
            "Stage IB Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Carcinoma in Situ", 
                "Carcinoma, Intraductal, Noninfiltrating", 
                "Carcinoma, Ductal, Breast", 
                "Carcinoma, Lobular"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVE:\n\n        1. Investigate the feasibility of a clinical trial administering ionizing radiation with\n           concurrent caloric restriction (CR) for the treatment of breast cancer.\n\n           SECONDARY OBJECTIVE:\n\n        2. Investigate measurable changes of patient characteristics and tissue and serum from CR\n           conditions to determine a metric for evaluating this treatment in future studies.\n\n      OUTLINE:\n\n      Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to\n      complete for 7-10 days. Dietary counselors then give patients guidelines for dietary\n      modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric\n      restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of\n      radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation\n      therapy once daily (QD) 5 days a week for 6 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Pathologically proven diagnosis of ductal carcinoma in situ (DCIS) or invasive breast\n             cancer\n\n          2. Ability to have breast conservation as determined by the judgment of the radiation\n             oncologist\n\n          3. The patient must be female\n\n          4. Age >= 18\n\n          5. Clinical (c)Stage 0 or cStage I\n\n          6. If multifocal breast cancer, then it must have been resected through a single\n             lumpectomy incision with negative margins\n\n          7. Appropriate stage for protocol entry, including no clinical evidence for distant\n             metastases, based upon the following minimum diagnostic workup:\n\n               1. History/physical examination, including breast exam and documentation of weight\n                  and Karnofsky performance status of 80-100% for at least 60 days prior to study\n                  entry\n\n               2. Ipsilateral mammogram within 6 months prior to study entry\n\n          8. Women of childbearing potential must have a negative serum pregnancy test within 14\n             days of study entry\n\n          9. Women of childbearing potential must be non-pregnant and non-lactating and willing to\n             use medically acceptable form of contraception during radiation therapy\n\n         10. Patient must capable of and provide study specific informed consent prior to study\n             entry\n\n         11. Body mass index (BMI) >= 21\n\n         12. Weight >= 100 lbs\n\n         13. No prior history of non-breast malignancies in the past 5 years unless it was a\n             non-melanomatous skin lesion or carcinoma in situ of the cervix\n\n         14. Patient must not be a candidate to receive chemotherapy\n\n         15. Patient must not have any of the following severe, active co-morbidity, defined as\n             follows:\n\n               1. Unstable angina and/or congestive heart failure requiring hospitalization within\n                  the last 6 months\n\n               2. Transmural myocardial infarction within the last 6 months\n\n               3. Acute bacterial or fungal infection requiring intravenous antibiotics at the\n                  time of registration\n\n               4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness\n                  requiring hospitalization or precluding study therapy within 30 days before\n                  registration\n\n               5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;\n                  note, however, that laboratory tests for liver function and coagulation\n                  parameters are not required for entry into this protocol\n\n               6. Acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)\n                  positive based upon current Centers for Disease and Control (CDC) definition;\n                  note, however, that HIV testing is not required for entry into this protocol;\n                  the need to exclude patients with AIDS or HIV from this protocol is necessary\n                  because anti-retrovirals may alter patient metabolism\n\n         16. Patient must not have active systemic lupus, erythematosus, or any history of\n             scleroderma, dermatomyositis with active rash\n\n         17. No prior radiotherapy to the ipsilateral breast or prior radiation to the region of\n             the breast that would result in overlap of radiation therapy fields\n\n         18. Patient must have a fasting glucose < 125 mg/mL and not be currently taking\n             hypoglycemic medications\n\n         19. Patient may not have any active gastrointestinal/malabsorption disorder at the\n             discretion of the Principal Investigator\n\n               1. Inflammatory bowel disease\n\n               2. Celiac disease\n\n               3. Chronic pancreatitis\n\n               4. Chronic diarrhea or vomiting\n\n               5. Active eating disorder\n\n         20. Creatinine < 1.7\n\n         21. Not currently taking steroids\n\n         22. No currently active pituitary secreting tumors up to physician discretion\n\n         23. No history of or current active drug/alcohol dependence\n\n         24. No patients being decisionally impaired\n\n        Exclusion Criteria:\n\n          1. Patient is not a candidate for breast conservation\n\n          2. Patient is male\n\n          3. Age < 18 years\n\n          4. cStage II or above\n\n          5. Patient has evidence of distant metastases\n\n          6. Karnofsky performance status less than 80% within 60 days prior to study\n\n          7. Ipsilateral mammogram done greater than 6 months prior to study\n\n          8. Women of childbearing potential with a positive serum beta human chorionic\n             gonadotropin (hCG)\n\n          9. Patient has a history of dementia, psychosis or other disorder affecting their mental\n             status to the point where they cannot consent or comply with study guidelines\n\n         10. BMI < 21\n\n         11. Weight < 100 lbs\n\n         12. Weight loss >= 10% in the last 3 months (mos)\n\n         13. Prior invasive non-breast malignancy (except non-melanomatous skin cancer, carcinoma\n             in situ of the cervix) unless disease free for a minimum of 5 years prior to\n             registration\n\n         14. Two or more breast cancers not resectable through a single lumpectomy incision\n\n         15. Non-epithelial breast malignancies such as sarcoma or lymphoma\n\n         16. Prior radiotherapy to the ipsilateral breast or prior radiation to the region of the\n             breast that would result in overlap of radiation therapy fields\n\n         17. Intention to administer concurrent chemotherapy for current breast cancer\n\n         18. Severe, active co-morbidity, defined as follows:\n\n               1. Unstable angina and/or congestive heart failure requiring hospitalization within\n                  the last 6 months\n\n               2. Transmural myocardial infarction within the last 6 months\n\n               3. Acute bacterial or fungal infection requiring intravenous antibiotics at the\n                  time of registration\n\n               4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness\n                  requiring hospitalization or precluding study therapy within 30 days before\n                  registration\n\n               5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;\n                  note, however, that laboratory tests for liver function and coagulation\n                  parameters are not required for entry into this protocol\n\n               6. Acquired immune deficiency syndrome (AIDS) or HIV positive based upon current\n                  CDC definition; note, however, that HIV testing is not required for entry into\n                  this protocol; the need to exclude patients with AIDS or HIV from this protocol\n                  is necessary because anti-retrovirals may alter patient metabolism\n\n         19. Active systemic lupus, erythematosus, or any history of scleroderma, dermatomyositis\n             with active rash\n\n         20. Fasting glucose > 125 or currently taking hypoglycemic medications\n\n         21. Active gastrointestinal/malabsorption disorder at the discretion of the Principal\n             Investigator\n\n               1. Inflammatory bowel disease\n\n               2. Celiac disease\n\n               3. Chronic pancreatitis\n\n               4. Chronic diarrhea or vomiting\n\n               5. Active eating disorder\n\n         22. Creatinine >= 1.7\n\n         23. Current use of steroids\n\n         24. Pituitary secreting tumors up to physician discretion\n\n         25. Active drug/alcohol dependence or abuse history\n\n         26. Decisionally impaired patients"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819233", 
            "org_study_id": "12G.616", 
            "secondary_id": "2012-94"
        }, 
        "intervention": [
            {
                "arm_group_label": "Behavioral dietary intervention", 
                "description": "Receive caloric restricted dietary intervention", 
                "intervention_name": "Behavioral dietary intervention", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Behavioral dietary intervention", 
                "description": "Undergo definitive lumpectomy", 
                "intervention_name": "Therapeutic conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Behavioral dietary intervention", 
                "description": "Undergo radiation therapy", 
                "intervention_name": "Radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "Irradiation", 
                    "Radiotherapy", 
                    "Radiation"
                ]
            }, 
            {
                "arm_group_label": "Behavioral dietary intervention", 
                "description": "Receive dietary counseling", 
                "intervention_name": "Counseling intervention", 
                "intervention_type": "Other", 
                "other_name": "Counseling and communications studies"
            }, 
            {
                "arm_group_label": "Behavioral dietary intervention", 
                "description": "Ancillary studies", 
                "intervention_name": "Quality-of-life assessment", 
                "intervention_type": "Procedure", 
                "other_name": "Quality of life assessment"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 18, 2014", 
        "link": [
            {
                "description": "Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center", 
                "url": "http://www.KimmelCancerCenter.org"
            }, 
            {
                "description": "Thomas Jefferson University Hospitals", 
                "url": "http://www.JeffersonHospital.org"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Nicole Simone, MD"
            }, 
            "contact_backup": {
                "last_name": "Radiation Oncology Protocol Office", 
                "phone": "215-955-8619"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19107"
                }, 
                "name": "Thomas Jefferson University"
            }, 
            "investigator": [
                {
                    "last_name": "Nicole Simone, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Daniel Monti, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Pramila Rani Anne, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Maria Werner-Wasik, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Adam Dicker, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Wenyin Shi, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Voichita Bar-Ad, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert Den, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Anne Rosenberg, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Adam Berger, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Gordon Schwartz, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Andrew Newberg, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients", 
        "overall_contact": {
            "last_name": "Nicole Simone, MD", 
            "phone": "215-955-8619"
        }, 
        "overall_contact_backup": {
            "last_name": "Radiation Oncology Protocol Office", 
            "phone": "215-955-8619"
        }, 
        "overall_official": {
            "affiliation": "Thomas Jefferson University", 
            "last_name": "Nicole Simone, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Computed along with a 95% exact confidence interval. Exact binomial test (with a one-sided alpha of 0.05) will be used to test whether adherence is greater than 60%.", 
            "measure": "Proportion of patients who are adherent to the diet restriction", 
            "safety_issue": "No", 
            "time_frame": "Up to week 12"
        }, 
        "reference": [
            {
                "PMID": "20097433", 
                "citation": "Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci. 2010 Feb;31(2):89-98. doi: 10.1016/j.tips.2009.11.004. Epub 2010 Jan 25. Review."
            }, 
            {
                "PMID": "12525670", 
                "citation": "Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med. 2003;54:131-52. Epub 2001 Dec 3. Review."
            }, 
            {
                "PMID": "19867833", 
                "citation": "Rous P. THE INFLUENCE OF DIET ON TRANSPLANTED AND SPONTANEOUS MOUSE TUMORS. J Exp Med. 1914 Nov 1;20(5):433-51."
            }, 
            {
                "PMID": "12016155", 
                "citation": "Berrigan D, Perkins SN, Haines DC, Hursting SD. Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. Carcinogenesis. 2002 May;23(5):817-22."
            }, 
            {
                "PMID": "10469616", 
                "citation": "Zhu Z, Jiang W, Thompson HJ. Effect of energy restriction on tissue size regulation during chemically induced mammary carcinogenesis. Carcinogenesis. 1999 Sep;20(9):1721-6."
            }, 
            {
                "PMID": "2337899", 
                "citation": "Lok E, Scott FW, Mongeau R, Nera EA, Malcolm S, Clayson DB. Calorie restriction and cellular proliferation in various tissues of the female Swiss Webster mouse. Cancer Lett. 1990 May 15;51(1):67-73."
            }, 
            {
                "PMID": "7937932", 
                "citation": "Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B, Wagner A, Lauer B, Schulte-Hermann R. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9995-9."
            }, 
            {
                "PMID": "9242428", 
                "citation": "Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R, Glazer PM. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997 Aug 1;57(15):3079-83."
            }, 
            {
                "PMID": "11038295", 
                "citation": "Perer ES, Madan AK, Shurin A, Zakris E, Romeguera K, Pang Y, Beech DJ. Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res. 2000 Nov;94(1):1-5."
            }, 
            {
                "PMID": "21696633", 
                "citation": "Donohoe CL, Doyle SL, Reynolds JV. Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr. 2011 Jun 22;3:12. doi: 10.1186/1758-5996-3-12."
            }, 
            {
                "PMID": "17167471", 
                "citation": "Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006 Dec 14;444(7121):840-6. Review."
            }, 
            {
                "PMID": "20145127", 
                "citation": "Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010 Feb 15;70(4):1564-72. doi: 10.1158/0008-5472.CAN-09-3228. Epub 2010 Feb 9."
            }, 
            {
                "PMID": "22984531", 
                "citation": "Safdie F, Brandhorst S, Wei M, Wang W, Lee C, Hwang S, Conti PS, Chen TC, Longo VD. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One. 2012;7(9):e44603. doi: 10.1371/journal.pone.0044603. Epub 2012 Sep 11."
            }, 
            {
                "PMID": "22735163", 
                "citation": "Arguin H, Dionne IJ, S\u00e9n\u00e9chal M, Bouchard DR, Carpentier AC, Ardilouze JL, Tremblay A, Leblanc C, Brochu M. Short- and long-term effects of continuous versus intermittent restrictive diet approaches on body composition and the metabolic profile in overweight and obese postmenopausal women: a pilot study. Menopause. 2012 Aug;19(8):870-6."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819233"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Analyzed via a paired t-test.", 
                "measure": "Change in body fat measurement as determined by the Durnin-Womersley 4-fold technique", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 4 weeks after completion of study"
            }, 
            {
                "description": "Assessed via mixed-effects regression.", 
                "measure": "Weight changes over time assessed by modeling BMI as a function of time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 4 weeks after completion of study"
            }, 
            {
                "description": "Assessed via mixed-effects regression.", 
                "measure": "Patterns of change over time in vital signs, insulin and other clinical labs", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 4 weeks after completion of study"
            }, 
            {
                "description": "Assessed via mixed-effects regression.", 
                "measure": "Patterns of change over time in serum markers", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 4 weeks after completion of study"
            }, 
            {
                "description": "Assessed via mixed-effects regression.", 
                "measure": "Patterns of change over time in psycho-social outcomes measured using the Functional Assessment of Cancer Therapy-Breast (FACT-B)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 4 weeks after completion of study"
            }, 
            {
                "description": "Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.", 
                "measure": "Local recurrence", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks after completion of study"
            }, 
            {
                "description": "Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.", 
                "measure": "Distant metastases", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks after completion of study"
            }, 
            {
                "description": "Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks after completion of study"
            }, 
            {
                "description": "Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks after completion of study"
            }
        ], 
        "source": "Thomas Jefferson University", 
        "sponsors": {
            "collaborator": {
                "agency": "Ladies of Port Richmond", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Thomas Jefferson University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}